Events | Today This Week This Month All Events
Interview Notice
Registration Deadline：2023-06-29 11:00
Contact：Xu Peizhi 18019788613
Media units,
The seventh event in the interview tour series themed “Promoting High-Quality Economic Development” for Chinese and foreign media is scheduled to be held on the afternoon of June 29 (Thursday). The specific theme on this interview trip is “scientific and technological innovation”, and the agenda is as follows:
13:30 Depart from People’s Square (West Gate, 200, Renmin Avenue)
First stop: Shanghai Information2 Software Inc
Second stop: SMO ClinPlus Co., Ltd.
Contact: Xu Peizhi 18019788613
Information Office of Shanghai Municipality
June 27, 2023
Company profiles
1.Shanghai Information2 Software Inc
Shanghai Information2 Software Inc, established in 2011 and headquartered in Shanghai, is a leading software company specializing in data replication. The company focuses on developing and promoting advanced information technologies such as byte-level dynamic replication, semantic-level database replication, and volume/block-level replication. These solutions find widespread application in disaster recovery, data protection, cloud data management, and other critical fields. By enabling data interconnection and facilitating the integration of fragmented data, Information2 Software plays a vital role in supporting the development of the digital economy. In a significant milestone, in 2023, Information2 Software successfully listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange. The company’s ongoing commitment to innovation, customer-centric approach, and strategic partnerships have allowed them to build a robust and comprehensive data management solution across various industries. This multi-level, multi-strategy, global, and ecosystem-based solution caters to the diverse needs of finance, medical care, education, operators, energy, manufacturing, and the Internet sectors. At the core of Information2 Software’s offerings lies their proprietary data replication technology. By leveraging this cutting-edge technology, the company provides users with a range of essential solutions, including data security, hybrid cloud disaster recovery, database synchronization, data migration, data copy management, and big data collection and distribution. These solutions cater to the specific application scenarios covered by the new production factor of data. By empowering businesses with data-driven capabilities, Information2 Software helps users transition from an Internet+ approach to a data+ paradigm, fostering their overall business growth.
As of June 25, 2023, Information2 Software boasts a highly skilled team comprising over 580 professionals. With a track record of serving more than 60,000 customers, the company has established itself as a trusted provider in the industry. Furthermore, it has cultivated strong partnerships with over 500 ecosystem collaborators across the industrial chain. This extensive network of alliances reinforces Information2 Software’s ability to deliver comprehensive solutions to a diverse range of sectors, including banking, securities, funds, telecommunications, and government enterprises. Recognized for its expertise and contributions, Information2 Software has received numerous honorary qualifications, underscoring its commitment to excellence. The company has been honored with distinctions such as Shanghai Science and Technology Little Giant Enterprise, Shanghai Specialized, Special and New SME, and Shanghai Enterprise Technology Center. These accolades reflect Information2 Software’s leading position in the field of enterprise business continuity and data replication management.
2.SMO ClinPlus Co., Ltd.
Established in 2013, SMO ClinPlus Co., Ltd. is dedicated to providing comprehensive SMO (Site Management Organization) services for both domestic and international pharmaceutical companies, medical device manufacturers, and other health-related product developers. Leveraging its extensive experience in executing clinical trial projects, ClinPlus offers a range of services, including preliminary preparation and planning, test site initiation, on-site execution, and overall project management. By delivering these comprehensive solutions, the company aims to streamline and expedite the execution of sponsors’ clinical trials, ensuring greater efficiency and effectiveness. With years of rapid growth and exceptional performance, ClinPlus has achieved a prominent position in the market. The company’s strengths lie in its robust project management capabilities, extensive project execution experience, and wide coverage of clinical trial institutions. Notably, ClinPlus has become the first SMO company in China to be listed on the domestic A-share market. Since its establishment, the company has successfully undertaken over 2,100 SMO projects, including 16 ADC projects, 19 bispecific antibody projects, 45 CAR-T projects, 100 anti-PD-1 and anti-PD-L1 projects, as well as numerous projects related to COVID-19. As of the end of June 2022, ClinPlus had implemented 1,184 SMO projects, contributing to the successful listing of more than 90 innovative drugs and medical device products worldwide. These projects span across 24 fields, such as oncology, endocrine diseases, medical devices, viral hepatitis, immune diseases, blood disorders, and infections. This extensive experience has allowed ClinPlus to accumulate a wealth of knowledge in both domestic and international clinical trial execution and management. The company has also established a comprehensive standardized management and quality control system to ensure consistent and high-quality service delivery.
ClinPlus offers a range of featured products as part of their clinical trial site management services. These products include the world’s first and only approved ADC drug targeting Trop-2, the first domestically developed bispecific antibody and the world's first approved PD-1/CTLA-4 bispecific antibody, China’s pioneering oral direct anti-HCV treatment, China’s first proprietary COVID-19 neutralizing antibody combination, the FDA-approved first drug for treating myelofibrosis, China’s first antibody for the treatment of hyperlipidemia, the world’s first approved Bruton’s tyrosine kinase (BTK) inhibitor, the world’s first approved biological agent for treating systemic lupus erythematosus (SLE), China’s first domestically produced human papillomavirus (HPV) vaccine for cervical cancer, and clinical trial projects for China’s initial batch of CAR-T treatments. As of June 30, 2022, ClinPlus boasted a team of more than 3,400 skilled professionals dedicated to their business operations. They serve over 740 drug clinical trial institutions, covering more than 1,100 clinical trial sites across more than 160 cities in China. Leveraging their talent advantages, ClinPlus is well-versed in ICH-GCP, GCP, and domestic and international laws and regulations. They strictly adhere to international standard operating procedures, closely attend to customer needs, and deliver efficient clinical trial site management services of exceptional quality and efficiency. Their SMO service sets an advanced industry standard, meeting international benchmarks. ClinPlus has earned several honorary qualifications, including recognition as a High-tech Enterprise, Shanghai Science and Technology Little Giant Enterprise, Zhangjiang Star 2021, and Shanghai Specialized, Special and New SME.
The seventh event in the interview tour series themed “Promoting High-Quality Economic Development” for Chinese and foreign media is scheduled to be held on the afternoon of June 29 (Thursday). The specific theme on this interview trip is “scientific and technological innovation”, and the agenda is as follows:
13:30 Depart from People’s Square (West Gate, 200, Renmin Avenue)
First stop: Shanghai Information2 Software Inc
Second stop: SMO ClinPlus Co., Ltd.
Contact: Xu Peizhi 18019788613
Information Office of Shanghai Municipality
June 27, 2023
Company profiles
1.Shanghai Information2 Software Inc
Shanghai Information2 Software Inc, established in 2011 and headquartered in Shanghai, is a leading software company specializing in data replication. The company focuses on developing and promoting advanced information technologies such as byte-level dynamic replication, semantic-level database replication, and volume/block-level replication. These solutions find widespread application in disaster recovery, data protection, cloud data management, and other critical fields. By enabling data interconnection and facilitating the integration of fragmented data, Information2 Software plays a vital role in supporting the development of the digital economy. In a significant milestone, in 2023, Information2 Software successfully listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange. The company’s ongoing commitment to innovation, customer-centric approach, and strategic partnerships have allowed them to build a robust and comprehensive data management solution across various industries. This multi-level, multi-strategy, global, and ecosystem-based solution caters to the diverse needs of finance, medical care, education, operators, energy, manufacturing, and the Internet sectors. At the core of Information2 Software’s offerings lies their proprietary data replication technology. By leveraging this cutting-edge technology, the company provides users with a range of essential solutions, including data security, hybrid cloud disaster recovery, database synchronization, data migration, data copy management, and big data collection and distribution. These solutions cater to the specific application scenarios covered by the new production factor of data. By empowering businesses with data-driven capabilities, Information2 Software helps users transition from an Internet+ approach to a data+ paradigm, fostering their overall business growth.
As of June 25, 2023, Information2 Software boasts a highly skilled team comprising over 580 professionals. With a track record of serving more than 60,000 customers, the company has established itself as a trusted provider in the industry. Furthermore, it has cultivated strong partnerships with over 500 ecosystem collaborators across the industrial chain. This extensive network of alliances reinforces Information2 Software’s ability to deliver comprehensive solutions to a diverse range of sectors, including banking, securities, funds, telecommunications, and government enterprises. Recognized for its expertise and contributions, Information2 Software has received numerous honorary qualifications, underscoring its commitment to excellence. The company has been honored with distinctions such as Shanghai Science and Technology Little Giant Enterprise, Shanghai Specialized, Special and New SME, and Shanghai Enterprise Technology Center. These accolades reflect Information2 Software’s leading position in the field of enterprise business continuity and data replication management.
2.SMO ClinPlus Co., Ltd.
Established in 2013, SMO ClinPlus Co., Ltd. is dedicated to providing comprehensive SMO (Site Management Organization) services for both domestic and international pharmaceutical companies, medical device manufacturers, and other health-related product developers. Leveraging its extensive experience in executing clinical trial projects, ClinPlus offers a range of services, including preliminary preparation and planning, test site initiation, on-site execution, and overall project management. By delivering these comprehensive solutions, the company aims to streamline and expedite the execution of sponsors’ clinical trials, ensuring greater efficiency and effectiveness. With years of rapid growth and exceptional performance, ClinPlus has achieved a prominent position in the market. The company’s strengths lie in its robust project management capabilities, extensive project execution experience, and wide coverage of clinical trial institutions. Notably, ClinPlus has become the first SMO company in China to be listed on the domestic A-share market. Since its establishment, the company has successfully undertaken over 2,100 SMO projects, including 16 ADC projects, 19 bispecific antibody projects, 45 CAR-T projects, 100 anti-PD-1 and anti-PD-L1 projects, as well as numerous projects related to COVID-19. As of the end of June 2022, ClinPlus had implemented 1,184 SMO projects, contributing to the successful listing of more than 90 innovative drugs and medical device products worldwide. These projects span across 24 fields, such as oncology, endocrine diseases, medical devices, viral hepatitis, immune diseases, blood disorders, and infections. This extensive experience has allowed ClinPlus to accumulate a wealth of knowledge in both domestic and international clinical trial execution and management. The company has also established a comprehensive standardized management and quality control system to ensure consistent and high-quality service delivery.
ClinPlus offers a range of featured products as part of their clinical trial site management services. These products include the world’s first and only approved ADC drug targeting Trop-2, the first domestically developed bispecific antibody and the world's first approved PD-1/CTLA-4 bispecific antibody, China’s pioneering oral direct anti-HCV treatment, China’s first proprietary COVID-19 neutralizing antibody combination, the FDA-approved first drug for treating myelofibrosis, China’s first antibody for the treatment of hyperlipidemia, the world’s first approved Bruton’s tyrosine kinase (BTK) inhibitor, the world’s first approved biological agent for treating systemic lupus erythematosus (SLE), China’s first domestically produced human papillomavirus (HPV) vaccine for cervical cancer, and clinical trial projects for China’s initial batch of CAR-T treatments. As of June 30, 2022, ClinPlus boasted a team of more than 3,400 skilled professionals dedicated to their business operations. They serve over 740 drug clinical trial institutions, covering more than 1,100 clinical trial sites across more than 160 cities in China. Leveraging their talent advantages, ClinPlus is well-versed in ICH-GCP, GCP, and domestic and international laws and regulations. They strictly adhere to international standard operating procedures, closely attend to customer needs, and deliver efficient clinical trial site management services of exceptional quality and efficiency. Their SMO service sets an advanced industry standard, meeting international benchmarks. ClinPlus has earned several honorary qualifications, including recognition as a High-tech Enterprise, Shanghai Science and Technology Little Giant Enterprise, Zhangjiang Star 2021, and Shanghai Specialized, Special and New SME.
Application Status
| 04-16 | 21315227 | Processing |
| 03-12 | 21315226 | Processing |
| 09-26 | 21315225 | Processing |
Inquiry Status
| 02-29 | 02131558 | Received |
| 03-06 | 02131557 | Received |
| 11-14 | 02131556 | Received |
FAQ
Q: Q: Is there a place where I can get...
A: A: Log on to http://touch.shio.gov....
A: A: Log on to http://touch.shio.gov....
Q: Q: What is the easiest way to set u...
A: A: 1. Log on to http://touch.shio.g...
A: A: 1. Log on to http://touch.shio.g...
Q: Where can I get an English map of S...
A: English maps of Shanghai are availa...
A: English maps of Shanghai are availa...
